{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2025,10,27]],"date-time":"2025-10-27T04:57:06Z","timestamp":1761541026627},"reference-count":37,"publisher":"American Society of Hematology","issue":"1","content-domain":{"domain":["ashpublications.org"],"crossmark-restriction":true},"short-container-title":[],"published-print":{"date-parts":[[2010,12,4]]},"abstract":"<jats:title>Abstract<\/jats:title><jats:p>Stroke prevention in atrial fibrillation (AF) is a rapidly expanding indication for lifelong oral anticoagulation. The vitamin K antagonists (VKAs) effectively prevent stroke, but are notoriously difficult to manage and are associated with frequent adverse events. These factors account for the widespread underuse of warfarin for patients with AF who are qualified candidates for therapy. New oral anticoagulants with different mechanisms of action are beginning to exit phase III trials and may replace the VKAs for a number of indications, especially AF. The oral direct thrombin and Xa inhibitors are furthest along in development. Dabigatran etexilate, a thrombin inhibitor, has recently shown excellent outcomes in the prevention of stroke in patients with AF. The oral Xa inhibitors are still in phase III trials for stroke prevention in AF, but results from trials for other indications look promising. These short-acting, short-duration, unmonitored drugs are not without limitations and potential adverse effects. The perceived drawbacks of the VKAs may actually be assets in the management of patients with AF, and the pros and cons of each class of drug must be taken into account as physicians consider or patients request transition to a new class of oral anticoagulants.<\/jats:p>","DOI":"10.1182\/asheducation-2010.1.221","type":"journal-article","created":{"date-parts":[[2011,1,16]],"date-time":"2011-01-16T19:08:48Z","timestamp":1295204928000},"page":"221-228","update-policy":"http:\/\/dx.doi.org\/10.1182\/blood.2019cm0000","source":"Crossref","is-referenced-by-count":29,"title":["Warfarin Versus New Agents: Interpreting the Data"],"prefix":"10.1182","volume":"2010","author":[{"given":"Jack","family":"Ansell","sequence":"first","affiliation":[{"name":"Department of Medicine, Lenox Hill Hospital, New York, NY"}],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"234","reference":[{"key":"2019111715500718400_B1","doi-asserted-by":"crossref","first-page":"2370","DOI":"10.1001\/jama.285.18.2370","article-title":"Prevalence of diagnosed atrial fibrillation in adults: national implications for rhythm management and stroke prevention: the AnTicoagulation and Risk Factors In Atrial Fibrillation (ATRIA) Study","volume":"285","author":"Go","year":"2001","journal-title":"JAMA"},{"key":"2019111715500718400_B2","doi-asserted-by":"crossref","first-page":"119","DOI":"10.1161\/CIRCULATIONAHA.105.595140","article-title":"Secular trends in incidence of atrial fibrillation in Olmsted County, Minnesota, 1980 to 2000, and implications on the projections for future prevalence","volume":"114","author":"Miyasaka","year":"2006","journal-title":"Circulation"},{"key":"2019111715500718400_B3","doi-asserted-by":"crossref","first-page":"2864","DOI":"10.1001\/jama.285.22.2864","article-title":"Validation of clinical classification schemes for predicting stroke: results from the National Registry of Atrial Fibrillation","volume":"285","author":"Gage","year":"2001","journal-title":"JAMA"},{"key":"2019111715500718400_B4","doi-asserted-by":"crossref","first-page":"857","DOI":"10.7326\/0003-4819-146-12-200706190-00007","article-title":"Meta-analysis: antithrombotic therapy to prevent stroke in patients who have nonvalvular atrial fibrillation","volume":"146","author":"Hart","year":"2007","journal-title":"Ann Intern Med"},{"key":"2019111715500718400_B5","doi-asserted-by":"crossref","first-page":"546S","DOI":"10.1378\/chest.08-0678","article-title":"Antithrombotic therapy in atrial fibrillation. ACCP evidence-based clinical practice guidelines","volume":"133","author":"Singer","year":"2008","journal-title":"Chest"},{"key":"2019111715500718400_B6","doi-asserted-by":"crossref","first-page":"160S","DOI":"10.1378\/chest.08-0670","article-title":"The pharmacology and management of the vitamin K antagonists: ACCP evidence-based clinical practice guidelines","volume":"133","author":"Ansell","year":"2008","journal-title":"Chest"},{"key":"2019111715500718400_B7","doi-asserted-by":"crossref","first-page":"755","DOI":"10.7326\/0003-4819-147-11-200712040-00006","article-title":"Medication use leading to emergency department visits for adverse drug events in older adults","volume":"147","author":"Budnitz","year":"2007","journal-title":"Ann Intern Med"},{"key":"2019111715500718400_B8","doi-asserted-by":"crossref","first-page":"41","DOI":"10.1097\/HPC.0b013e3181d24562","article-title":"The use of antithrombotic therapies in the prevention and treatment of arterial and venous thrombosis","volume":"9","author":"Arepally","year":"2010","journal-title":"Crit Path Cardiol"},{"key":"2019111715500718400_B9","doi-asserted-by":"crossref","first-page":"1691","DOI":"10.1016\/S0140-6736(03)14841-6","article-title":"Stroke prevention with the oral direct thrombin inhibitor ximelagatran compared with warfarin in patients with non-valvular atrial fibrillation. Randomized controlled trial","volume":"362","author":"Executive Steering Committee on behalf of the SPORTIF III Investigators","year":"2003","journal-title":"Lancet"},{"key":"2019111715500718400_B10","doi-asserted-by":"crossref","first-page":"690","DOI":"10.1001\/jama.293.6.690","article-title":"Ximelagatran vs warfarin for stroke prevention in patients with non-valvular atrial fibrillation","volume":"293","author":"SPORTIF Executive Steering Committee for the SPORTIF V Investigators","year":"2005","journal-title":"JAMA"},{"key":"2019111715500718400_B11","first-page":"1","article-title":"Oral anticoagulation with factor Xa and thrombin inhibitors: on the threshold of change","volume":"16","author":"Carreiro Zikria","year":"2009","journal-title":"Curr Opin Hematol"},{"key":"2019111715500718400_B12","doi-asserted-by":"crossref","first-page":"2178","DOI":"10.1111\/j.1538-7836.2007.02748.x","article-title":"Oral dabigatran etexilate vs subcutaneous enoxaparin for the prevention of venous thromboembolism after total knee replacement: the RE-MODEL randomized trial","volume":"5","author":"Eriksson","year":"2007","journal-title":"J Thromb Haemost"},{"key":"2019111715500718400_B13","doi-asserted-by":"crossref","first-page":"949","DOI":"10.1016\/S0140-6736(07)61445-7","article-title":"Dabigatran etexilate versus enoxaparin for prevention of venous thromboembolism after total hip replacement: a randomised, double-blind, non-inferiority trial","volume":"370","author":"Eriksson","year":"2007","journal-title":"Lancet"},{"key":"2019111715500718400_B14","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1016\/j.arth.2008.01.132","article-title":"Oral thrombin inhibitor dabigatran etexilate vs North American enoxaparin regimen for prevention of venous thromboembolism after knee arthroplasty surgery","volume":"24","author":"The RE-MOBILIZE Writing Committee","year":"2009","journal-title":"J Arthroplasty"},{"key":"2019111715500718400_B15","doi-asserted-by":"crossref","first-page":"2342","DOI":"10.1056\/NEJMoa0906598","article-title":"Dabigatran versus warfarin in the treatment of acute venous thromboembolism","volume":"361","author":"Schulman","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111715500718400_B16","doi-asserted-by":"crossref","first-page":"1419","DOI":"10.1016\/j.amjcard.2007.06.034","article-title":"Dabigatran with or without concomitant aspirin compared with warfarin alone in patients with nonvalvular atrial fibrillation (PETRO Study)","volume":"100","author":"Ezekowitz","year":"2007","journal-title":"Am J Cardiol"},{"key":"2019111715500718400_B17","doi-asserted-by":"crossref","first-page":"1139","DOI":"10.1056\/NEJMoa0905561","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Connolly","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111715500718400_B18","first-page":"2672","article-title":"Dabigatran versus warfarin in patients with atrial fibrillation","volume":"361","author":"Moia","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111715500718400_B19","doi-asserted-by":"crossref","first-page":"2765","DOI":"10.1056\/NEJMoa0800374","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after hip arthroplasty","volume":"358","author":"Eriksson","year":"2008","journal-title":"N Engl J Med"},{"key":"2019111715500718400_B20","doi-asserted-by":"crossref","first-page":"31","DOI":"10.1016\/S0140-6736(08)60880-6","article-title":"Extended duration rivaroxaban versus short-term enoxaparin for the prevention of venous thromboembolism after total hip arthroplasty: a double-blind, randomized controlled trial","volume":"372","author":"Kakkar","year":"2008","journal-title":"Lancet"},{"key":"2019111715500718400_B21","doi-asserted-by":"crossref","first-page":"2776","DOI":"10.1056\/NEJMoa076016","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty","volume":"358","author":"Lassen","year":"2008","journal-title":"N Engl J Med"},{"key":"2019111715500718400_B22","doi-asserted-by":"crossref","first-page":"1673","DOI":"10.1016\/S0140-6736(09)60734-0","article-title":"Rivaroxaban versus enoxaparin for thromboprophylaxis after total knee arthroplasty (RECORD4): a randomised trial","volume":"373","author":"Turpie","year":"2009","journal-title":"Lancet"},{"key":"2019111715500718400_B23","doi-asserted-by":"crossref","first-page":"340","DOI":"10.1016\/j.ahj.2009.11.025","article-title":"Rivaroxaban-once daily, oral, direct factor Xa inhibition compared with vitamin K antagonism for prevention of stroke and embolism trial in atrial fibrillation: rationale and design of the ROCKET AF Study","volume":"159","author":"Executive Steering Committee on behalf of the ROCKET AF Study Investigators","year":"2010","journal-title":"Am Heart J"},{"key":"2019111715500718400_B24","doi-asserted-by":"crossref","first-page":"LBA","DOI":"10.1182\/blood.V114.22.LBA-2.LBA-2","article-title":"Once daily oral rivaroxaban versus placebo in the long-term prevention of recurrent symptomatic venous thromboembolism, the Einstein-Extension Study","volume":"114","author":"Buller","year":"2009","journal-title":"Blood"},{"key":"2019111715500718400_B25","doi-asserted-by":"crossref","first-page":"1937","DOI":"10.1517\/13543780802528625","article-title":"Apixaban, an oral direct factor Xa inhibitor: awaiting the verdict","volume":"17","author":"Carreiro","year":"2008","journal-title":"Exp Opin Investig Drugs"},{"key":"2019111715500718400_B26","doi-asserted-by":"crossref","first-page":"594","DOI":"10.1056\/NEJMoa0810773","article-title":"Apixaban or enoxaparin for thromboprophylaxis after knee replacement","volume":"361","author":"Lassen","year":"2009","journal-title":"N Engl J Med"},{"key":"2019111715500718400_B27","doi-asserted-by":"crossref","first-page":"807","DOI":"10.1016\/S0140-6736(09)62125-5","article-title":"Apixaban versus enoxaparin for thromboprophylaxis after knee replacement: a randomized double-blind trial","volume":"375","author":"Lassen","year":"2010","journal-title":"Lancet"},{"key":"2019111715500718400_B28","first-page":"363","article-title":"Randomized, double-blind comparison of Apixaban and Enoxaparin for Thromboprophylaxis after hip replacement: The ADVANCE-3 Trial","author":"Lassen","year":"2010","journal-title":"N Engl J Med"},{"key":"2019111715500718400_B29","doi-asserted-by":"crossref","first-page":"131","DOI":"10.1016\/j.ahj.2009.07.035","article-title":"Apixaban for Reduction In Stroke and Other Thromboembolic Events in Atrial Fibrillation (ARISTOTLE) trial: design and rationale","volume":"159","author":"Lopes","year":"2010","journal-title":"Am Heart J"},{"key":"2019111715500718400_B30","article-title":"A phase 2, randomized, parallel group, dose-finding, multicenter, multinational study of the safety, tolerability and pilot efficacy of three blinded doses of the oral factor Xa inhibitor betrixaban compared with open-label dose-adjusted warfarin in patients with non-valvular atrial fibrillation (EXPLORE-Xa)","author":"Ezekowitz"},{"issue":"11","key":"2019111715500718400_B31","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.33.33","article-title":"Randomized, parallel group, multicenter, multinational study evaluating safety of DU-176b compared with warfarin in subjects with non-valvular atrial fibrillation [abstract 33]","volume":"112","author":"Weitz","year":"2008","journal-title":"Blood"},{"key":"2019111715500718400_B32","doi-asserted-by":"crossref","first-page":"1029","DOI":"10.1161\/CIRCULATIONAHA.109.856120","article-title":"The first evaluation of a novel vitamin K antagonist, tecarfarin (ATI-5923), in patients with atrial fibrillation","volume":"120","author":"Ellis","year":"2009","journal-title":"Circulation"},{"issue":"22","key":"2019111715500718400_B33","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V114.22.3135.3135","article-title":"Results of the EmbraceAC trial: a head-to-head comparison of warfarin with tecarfarin, a new anticoagulant [abstract 3135]","volume":"114","author":"Garcia","year":"2009","journal-title":"Blood"},{"key":"2019111715500718400_B34","doi-asserted-by":"crossref","first-page":"34","DOI":"10.1160\/TH09-06-0361","article-title":"New oral anticoagulants: will the potential advantages be achieved?","volume":"103","author":"Phillips","year":"2010","journal-title":"Thromb Haemost"},{"key":"2019111715500718400_B35","doi-asserted-by":"crossref","first-page":"1","DOI":"10.2165\/0003088-200948010-00001","article-title":"Comparative pharmacodynamics and pharmacokinetics of oral direct thrombin and factor Xa inhibitors in development","volume":"48","author":"Eriksson","year":"2009","journal-title":"Clin Pharmacokinet"},{"issue":"11","key":"2019111715500718400_B36","doi-asserted-by":"crossref","DOI":"10.1182\/blood.V112.11.983.983","article-title":"Recombinant antidote for reversal of anticoagulation by factor Xa inhibitors [abstract 983]","volume":"112","author":"Lu","year":"2008","journal-title":"Blood"},{"key":"2019111715500718400_B37","unstructured":"Fox M ed Dunham W Walsh E Cash-strapped US patients may be skipping drugs Reuters Web site Accessed February 10, 2009 http:\/\/www.reuters.com\/article\/healthNews\/idUSTRE5196SR20090211"}],"container-title":["Hematology"],"original-title":[],"language":"en","link":[{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/221\/1493811\/bep00110000221.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"syndication"},{"URL":"http:\/\/ashpublications.org\/hematology\/article-pdf\/2010\/1\/221\/1493811\/bep00110000221.pdf","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2020,6,15]],"date-time":"2020-06-15T18:04:42Z","timestamp":1592244282000},"score":1,"resource":{"primary":{"URL":"https:\/\/ashpublications.org\/hematology\/article\/2010\/1\/221\/96368\/Warfarin-Versus-New-Agents-Interpreting-the-Data"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,12,4]]},"references-count":37,"journal-issue":{"issue":"1","published-print":{"date-parts":[[2010,12,4]]}},"URL":"https:\/\/doi.org\/10.1182\/asheducation-2010.1.221","relation":{},"ISSN":["1520-4391","1520-4383"],"issn-type":[{"value":"1520-4391","type":"print"},{"value":"1520-4383","type":"electronic"}],"subject":[],"published":{"date-parts":[[2010,12,4]]}}}